Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has a beta value of 0.95 and has seen 12.69 million shares traded in the last trading session. The company, currently valued at $2.21B, closed the last trade at $5.50 per share which meant it gained $0.18 on the day or 3.38% during that session. The RXRX stock price is -124.73% off its 52-week high price of $12.36 and 31.09% above the 52-week low of $3.79. If we look at the company’s 10-day average daily trading volume, we find that it stood at 31.02 million shares traded. The 3-month trading volume is 25.67 million shares.
The consensus among analysts is that Recursion Pharmaceuticals Inc (RXRX) is Buy stock at the moment, with a recommendation rating of 2.43. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.52.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Sporting 3.38% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RXRX stock price touched $5.50 or saw a rise of 8.33%. Year-to-date, Recursion Pharmaceuticals Inc shares have moved -18.64%, while the 5-day performance has seen it change 21.95%. Over the past 30 days, the shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have changed -16.41%. Short interest in the company has seen 88.5 million shares shorted with days to cover at 4.7.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 8.33% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -9.09% off the targeted high while a plunge would see the stock gain -9.09% from current levels.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
The company’s shares have lost -17.54% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 50.09%.
6 analysts offering their estimates for the company have set an average revenue estimate of 18.08M for the current quarter. 6 have an estimated revenue figure of 19.78M for the next ending quarter. Year-ago sales stood 13.79M and 14.42M respectively for this quarter and the next, and analysts expect sales will grow by 31.10% for the current quarter and 50.09% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -35.28% over the past 5 years. Earnings growth for 2025 is a modest 5.03% while over the next 5 years, the company’s earnings are expected to increase by 20.68%.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next earnings report on 2025-Feb-27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Insiders own 3.57% of the company shares, while shares held by institutions stand at 77.45% with a share float percentage of 80.32%. Investors are also buoyed by the number of investors in a company, with Recursion Pharmaceuticals Inc having a total of 420.0 institutions that hold shares in the company. The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 28.14 million shares worth more than $211.07 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 11.6199% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 26.59 million shares as of 2024-06-30. The firm’s total holdings are worth over $199.42 million and represent 10.9787% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . As of Mar 31, 2025 , the former fund manager holds about 4.88% shares in the company for having 19.28 shares of worth $106.06 million while later fund manager owns 12.61 shares of worth $69.34 million as of Mar 31, 2025 , which makes it owner of about 3.19% of company’s outstanding stock.
